obesity drug news today glp-1 2025 oct 27 Weight-Loss Demonstration Begins July 2026 Medicare $50 GLP-1 Weight Loss

Consider your practical constraints

The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes

What should I eat if I'm on a GLP-1 medication

Based on the currently available evidence, GLP-1 RAs should not be used in patients with a family history of MTC or MEN2A, MEN2B

Diabetes Care 47 , 13501359 (2024)

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of G et G oal- s